( Toronto:RVX )

News from Resverlogix Corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 10, 2017, 07:00 ET Resverlogix selecciona el primer paciente para el ensayo clínico de fase 3 BETonMACE

- Resverlogix selecciona aleatoriamente el primer paciente en Taiwán y China para el ensayo clínico de fase 3 BETonMACE Resverlogix Corp....


Jul 10, 2017, 07:00 ET Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

CALGARY, July 10, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been...


Jun 28, 2017, 07:00 ET Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Jun 05, 2017, 06:55 ET Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

CALGARY, June 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted...


May 31, 2017, 08:39 ET Resverlogix celebra un simposio centrado en epigenética en el ERA-EDTA Congress de Madrid, España

El simposio titulado "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" del ERA-EDTA Congress destaca la inhibición BET y...


May 31, 2017, 07:00 ET Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain

The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and...


May 30, 2017, 07:00 ET Resverlogix recibe la aprobación de Health Canada para proceder con el ensayo clínico en enfermedad de Fabry

Apabetalone se expande para ser el primer ensayo clínico de enfermedad huérfana en pacientes con enfermedad de Fabry Resverlogix Corp....


May 30, 2017, 07:00 ET Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease CALGARY, May 30, 2017 /PRNewswire/ - Resverlogix...


May 23, 2017, 11:36 ET Reciente publicación y solicitud de patente de apabetalone apoya su desarrollo continuado y éxito

Nature Reviews Nephrology y Pfizer Inc. tratan la inhibición bromodominio BET y apabetalone como candidatos a fármacos viables Resverlogix...


May 23, 2017, 07:00 ET Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates CALGARY, May 23, 2017...


May 15, 2017, 12:09 ET Resverlogix recibe aprobación de la FDA para un ensayo clínico de Apabetalone

- Resverlogix recibe la aprobación de la División Cardiovascular y Renal de la FDA para proceder a un ensayo clínico solicitado de Apabetalone...


May 15, 2017, 09:35 ET Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

Apabetalone expands to a second major clinical indication in kidney dialysis patients CALGARY, May 15, 2017 /PRNewswire/ - Resverlogix Corp....


Mar 17, 2017, 07:00 ET Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Mar 15, 2017, 07:00 ET Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of...


Feb 23, 2017, 07:00 ET Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Protocol comments and recommendations incorporated CALGARY, Feb. 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:...


Feb 13, 2017, 07:00 ET Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

Emergence of new potential indications for apabetalone (RVX-208) via third party research CALGARY, Feb. 13, 2017 /PRNewswire/ - Resverlogix Corp....


Jan 23, 2017, 07:00 ET Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone CALGARY, Jan. 23,...


Jan 23, 2017, 07:00 ET Resverlogix proporciona resultados revolucionarios en pacientes con discapacidad renal severa

Varias proteínas clave que impulsan la enfermedad del riñón (renal) y el riesgo de diálisis están poco reguladas tras una sola dosis de...


Jan 05, 2017, 17:43 ET Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th...


Dec 15, 2016, 23:24 ET Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

CALGARY, Dec. 15, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and...


Dec 13, 2016, 18:28 ET Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

CALGARY, Dec. 13, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited...


Dec 05, 2016, 12:13 ET Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Nov 17, 2016, 08:00 ET Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

The successful completion of this Phase 1 pharmacokinetic (PK) trial in patients with severe renal impairment clears the path for the Company to...


Oct 06, 2016, 18:15 ET Resverlogix Announces Annual and Special Meeting of Shareholders

TORONTO, Oct. 6, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has rescheduled its...


Oct 04, 2016, 07:00 ET Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease

CALGARY, Oct. 4, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) will host R&D update events in New York, NY...